Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Novo Nordisk is part of Rapid Routes to Scale; a unique group of stakeholders from the academic, social and private sectors, committed to ensuring people in low and middle income countries have better health by understanding how primary care can be scaled and acting upon it.
Members include ICSF, The Bill & Melinda Gates Foundation, The Center for Health Market Innovations, GlaxoSmithKline,Innovations in Healthcare (formerly The International Partnership for Innovative Healthcare Delivery), Save the Children, Merck & Co,Merck Serono and T-HOPE at The University of Toronto.
Rapid Routes to Scale undertook the first ever global in-depth study to identify healthcare innovations in developing countries that have the potential to be replicated to increase accessibility to affordable medicine. Find out more here.